Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution

Sonali Lakshminarayanan, Indira Sahdev, Meena Goyal, Adrianna Vlachos, Mark Atlas, Jeffrey M. Lipton

Research output: Contribution to journalArticlepeer-review

Abstract

We report the low incidence of hepatic VOD in pediatric patients with various diagnoses including hematologic malignancies and non-malignant conditions transplanted at our institution. Retrospective review of 188 patients who underwent HSCT and received a combined prophylactic regimen of intravenous heparin, oral glutamine, and ursodiol was undertaken. Analysis of the outcome of VOD revealed only one clinical case with acute myeloid leukemia; the patient developed hepatic VOD 10 days after receiving myeloablative chemotherapy with busulfan and CTX followed by HLA-matched related peripheral blood stem cell transplantation. The low incidence of hepatic VOD in an otherwise high-risk pediatric transplant population is an important observation, which may be partly attributed to this prophylactic regimen, and warrants further randomized clinical trials for confirmation.

Original languageEnglish (US)
Pages (from-to)618-621
Number of pages4
JournalPediatric transplantation
Volume14
Issue number5
DOIs
StatePublished - Aug 2010
Externally publishedYes

Keywords

  • glutamine
  • heparin
  • ursodiol
  • veno-occlusive disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Fingerprint

Dive into the research topics of 'Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution'. Together they form a unique fingerprint.

Cite this